Trinity Delta is the leading provider of issuer-paid equity research for the healthcare and life sciences sectors. We have an experienced, integrated team of analysts providing the highest quality services to companies and to investors. Our expertise in biotech, medtech, specialty pharma and consumer health sectors enable a deep understanding of our clients and their ambitions, which is translated into accessible, impactful and timely research, clearly outlining the investment case.
Under MiFID II, whether you are an asset manager or a private investor, you can receive Trinity Delta research.
Our research is paid for by our corporate clients and we do not carry out any execution business. We do and will continue to make it freely available to all investors via multiple platforms (Trinity Delta and MiFID II).
Specialist sector research
Listed and private company coverage
Active investor interactions
Sharing exciting investment ideas
Institutional quality reports
Focused on what matters
Broad product suite
Valued by generalists and specialists
Global distribution
Targeting a wide audience
Fully MiFID II Compliant
Research freely available to everyone
We pride ourselves for our integrity and professionalism. Our word is our bond.
Integrity
Key to all our actions
Quality
Setting high standards
Clients always come first
Supporting your objectives
Trusted advisors
Collaboration and mutual respect